10x Genomics, Inc.
TXGHealthcareNASDAQMedical Devices · Last scanned Oct 24, 2026
Scan Results
Daily timeframe10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia. Valued at $9.32B, TXG is a mid-cap name in its sector. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits.
Market Cap
$9.32B
Beta
1.99
P/E (TTM)
—
P/E (Fwd)
933.22
EPS (TTM)
$-0.55
EPS (Fwd)
$0.08
ROE
-9.4%
ROA
-5.1%
Cash
$552.0M
Total Debt
$78.8M
Free CF
$179.7M
52W Change
419.6%
Annual Financials
Cash vs Debt
Where TXG stands vs its 150-day and 200-day moving averages
As of the October 12, 2026 close, TXG finished 92.25% above its 150-day moving average ($41.95) and 121.51% above its 200-day moving average ($36.41). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TXG overbought or oversold?
At the October 12, 2026 close, TXG's RSI(14) was 51.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $552.0M in cash comfortably exceeding the $78.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $179.7M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -9.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $516.4M (2022) to $642.8M (2025), reflecting a 24% increase over the period.
With a beta above 1.5, TXG tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, TXG has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing TXG's risk profile alongside its fundamentals and technical indicators provides a more complete picture.